Clinical Trials Logo

Sarcoma clinical trials

View clinical trials related to Sarcoma.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT06113315 Enrolling by invitation - Sarcoma Clinical Trials

A Study of Immunotherapy Treatment in People With Sarcoma

Start date: October 27, 2023
Phase:
Study type: Observational

The purpose of this study is to collect information from participants' medical records to improve our knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma. Immunotherapy drugs boost the immune system's ability to fight cancer by blocking proteins that act as a "brake" on the immune system. Blocking these proteins is like releasing the brakes, so that the immune system can target cancer cells and destroy them. This action is sometimes described as "immune checkpoint blockade.

NCT ID: NCT05844813 Enrolling by invitation - Clinical trials for Retroperitoneal Sarcoma

Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma

NATARS
Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal sarcoma. The main questions it aims to answer are: - Whether the 1,3-year progression-free survival time(PFS) is prolonged in the neoadjuvant therapy group, compared with the surgery-only group. - The Overall survival time in the two groups. - The safety and tolerance in the neoadjuvant therapy group. Participants will be allocated into two groups once they meet the inclusion criteria. - Surgery-only Group: Patients will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy. - Neoadjuvant therapy group: Patients will receive the neoadjuvant chemotherapy combined with target treatment for three circles before the following sarcoma resectional surgeries.

NCT ID: NCT05396118 Enrolling by invitation - Breast Cancer Clinical Trials

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Start date: May 18, 2022
Phase: Phase 2
Study type: Interventional

Prospective phase 2a clinical trial to demonstrate proof-of-concept for simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG for positron emission tomography (PET) and MRS (magnetic resonance spectroscopy) in a PET/MR scanner in patients with cancer.

NCT ID: NCT05266196 Enrolling by invitation - Ewing Sarcoma Clinical Trials

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Start date: January 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.

NCT ID: NCT03244020 Enrolling by invitation - Sarcoma Clinical Trials

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

Start date: February 16, 2018
Phase: Phase 4
Study type: Interventional

Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures.

NCT ID: NCT03134742 Enrolling by invitation - Clinical trials for Soft Tissue Sarcoma Adult

Radiation Effects on Bone

Start date: March 13, 2017
Phase:
Study type: Observational

Post-radiotherapy fragility fractures (caused by weakened bones) are an occasional complication of orthopedic oncology of soft tissue sarcoma patients. Treatment for impending fracture due to radiotherapy does exist in the form of operative stabilization, to prevent the bone from breaking. Without the ability to predict those patients at a higher risk for fracture, indications for treatment are difficult to determine. This study is to determine if there is a correlation between patients undergoing radiotherapy for soft tissue sarcoma and loss of bone density. The study wll evaluate bone loss for short and long term fracture prediction using dual-energy xray, absorptiometry (DEXA [DXA]) and computerized tomography scans (CT Scans)

NCT ID: NCT03054792 Enrolling by invitation - Rhabdomyosarcoma Clinical Trials

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, Magnetic Resonance Spectroscopy (MRS) and 18F-FAZA PET-MRI with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (7-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.

NCT ID: NCT02875548 Enrolling by invitation - Clinical trials for Advanced Solid Tumors

A Study to Assess the Long-term Safety of Tazemetostat

TRuST
Start date: August 30, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy. The aim of the study will be to assess the long-term safety of tezemetostat.

NCT ID: NCT01883518 Enrolling by invitation - Sarcoma Clinical Trials

Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma

ADCVCTAST
Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas

NCT ID: NCT00807261 Enrolling by invitation - Sarcoma Clinical Trials

Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy

Start date: September 2008
Phase: Phase 2
Study type: Interventional

To determine the activity of weekly Docetaxel and Gemcitabine in patients with advanced soft tissue sarcoma previously treated with anthracycline and/or ifosfamide 1. Primary endpoint: response rate 2. Secondary endpoint: progress-free survival, overall survival, safety